Hepatitis A Vaccine Allergy: Rare Reactions, Common Misattributions, and Safe Vaccination
True IgE-mediated allergic reactions to the hepatitis A vaccine are exceedingly rare, occurring in approximately 1 per 1 million doses administered. Most reported 'reactions' are common, non-allergic injection-site responses such as soreness, redness, or mild fever. The vaccine contains inactivated virus, aluminum adjuvant, and trace residual components from the manufacturing process. For the very small number of patients with a confirmed hypersensitivity, evaluation by a board-certified allergist can identify the specific trigger and guide safe vaccination strategies, including graded-dose administration when medically necessary.
Free · 5 min · Insurance accepted
What Is Hepatitis A Vaccine Allergy?
Hepatitis A vaccine 'allergy' is a widely misunderstood clinical entity.
True IgE-mediated allergic reactions to the hepatitis A vaccine are extraordinarily rare — estimated at approximately 1 per 1 million doses administered — and the overwhelming majority of post-vaccination symptoms reported by patients are non-allergic, self-limited injection-site reactions or constitutional symptoms that reflect a normal immune response to vaccination, not an allergic hypersensitivity.
The hepatitis A vaccine is an inactivated (killed) whole-virus vaccine, meaning it contains no live virus and cannot cause hepatitis A infection. Two single-antigen formulations are available in the United States: Havrix (GlaxoSmithKline) and Vaqta (Merck), as well as a combination hepatitis A/hepatitis B vaccine (Twinrix). All are administered intramuscularly, typically in a two-dose series given 6–18 months apart.
When a patient reports an 'allergy' to the hepatitis A vaccine, the clinical question is rarely whether they are truly allergic — it is whether their reported symptoms represent a common immunologic response, a vasovagal episode, an anxiety reaction, or, in the very rarest of cases, a genuine IgE-mediated hypersensitivity to a vaccine component. A board-certified allergist can distinguish between these possibilities and, when appropriate, guide safe re-vaccination.
Symptoms of Hepatitis A Vaccine Reactions
Recognizing symptoms early helps you get the right treatment faster.
Injection-site soreness
mildLocal pain, tenderness, and mild swelling at the injection site is the most common post-vaccination symptom, occurring in 20–50% of adults and reflecting a normal inflammatory response.
Injection-site redness and swelling
mildErythema and induration at the injection site are common local reactions, typically peaking at 24 hours and resolving within 48 hours without treatment.
Low-grade fever
mildA temperature of 99–101°F occurs in 10–15% of vaccine recipients as part of the normal immune response and is not a sign of allergy.
Fatigue and malaise
mildGeneralized tiredness and feeling unwell for 24–48 hours post-vaccination reflects immune activation and is not an allergic symptom.
Headache
mildMild to moderate headache occurs in a subset of vaccine recipients and is typically self-limited, resolving within 24 hours.
Vasovagal syncope (fainting)
mildFainting, dizziness, and pallor triggered by needle pain or anxiety can mimic an allergic reaction but is a benign vasovagal response, not an IgE-mediated event.
Urticaria (hives) — rare allergic symptom
moderateGeneralized hives developing within minutes to hours of vaccination may indicate IgE-mediated hypersensitivity to a vaccine component and should prompt evaluation by an allergist before subsequent doses.
Anaphylaxis — extremely rare
severeAnaphylaxis with urticaria, angioedema, bronchospasm, and hypotension occurs in approximately 1 per 1 million hepatitis A vaccine doses and is a medical emergency requiring immediate epinephrine and emergency care.
When to see a doctor
The symptoms that follow hepatitis A vaccination span a wide spectrum from the expected and benign to the rare and serious. It is essential to distinguish between common post-vaccination symptoms — which are normal and do not contraindicate future doses — and the very rare signs of a true allergic reaction that require immediate medical attention. The most common symptoms are local injection-site reactions: soreness, redness, and swelling at the injection site, occurring in 20–50% of adult recipients and typically resolving within 24–48 hours. Systemic symptoms including low-grade fever, fatigue, headache, and malaise occur in 10–15% of recipients and reflect the body's normal immune response to the vaccine. True allergic symptoms — urticaria (hives), angioedema (swelling of the lips, face, or throat), wheezing, difficulty breathing, and hypotension — are extremely rare, occurring in approximately 1 per 1 million doses. These symptoms typically begin within minutes to one hour of vaccination. If you experience throat tightness, difficulty breathing, or a sensation of impending doom after vaccination, seek emergency medical care immediately.
Hepatitis A Vaccine and Asthma
There is no established association between hepatitis A vaccination and asthma exacerbation. The hepatitis A vaccine is an inactivated vaccine, and inactivated vaccines are generally considered safe for patients with asthma, including those with severe or poorly controlled disease. The CDC does not list asthma as a contraindication or precaution for hepatitis A vaccination. Patients with asthma who are concerned about vaccine-related respiratory symptoms should discuss their specific concerns with their allergist, but the available evidence does not support a causal link between hepatitis A vaccination and asthma worsening. As with any medical procedure, patients with severe asthma should ensure their asthma is well-controlled at the time of vaccination and have their rescue inhaler available.
Potential Complications of Hepatitis A Vaccine Reactions
The complications of hepatitis A vaccine reactions depend on whether the reaction is a common local response or a true allergic hypersensitivity. For the vast majority of patients who experience only injection-site soreness, fever, or fatigue, there are no long-term complications — these symptoms resolve completely within 48 hours without sequelae. For the extremely rare patient who experiences a true IgE-mediated reaction, the primary complication is the risk of anaphylaxis with subsequent doses if the responsible allergen is not identified and managed. Anaphylaxis is a life-threatening emergency that can cause airway compromise, cardiovascular collapse, and death if not treated promptly with intramuscular epinephrine. However, with appropriate allergist evaluation — including skin testing to vaccine components and, when indicated, graded-dose challenge — most patients with a suspected vaccine allergy can safely receive future doses. A secondary complication is unnecessary vaccine avoidance. Patients who misinterpret a normal post-vaccination symptom as an allergy may decline future hepatitis A vaccination, leaving themselves unprotected against a vaccine-preventable disease that can cause severe liver injury. The risk of hepatitis A infection in unvaccinated at-risk individuals far exceeds the minuscule risk of a true allergic reaction to the vaccine.
Anaphylaxis with subsequent doses
In the very rare patient with a confirmed IgE-mediated allergy to a vaccine component, re-exposure without proper evaluation and management could trigger recurrent anaphylaxis.
Unnecessary vaccine avoidance
Misattribution of normal post-vaccination symptoms as 'allergy' may lead patients to decline future hepatitis A vaccination, increasing their risk of acquiring a preventable infection.
Diagnostic uncertainty
Without proper allergist evaluation, patients with a reported vaccine reaction may carry an 'allergy' label that complicates future medical care without providing clinical benefit.
What Causes Reactions to the Hepatitis A Vaccine?
The causes of post-vaccination symptoms fall into three distinct categories, only one of which is a true allergy. The most common category — accounting for well over 99% of reported events — is the expected immunologic and local response to vaccination. The intramuscular injection of inactivated viral particles with an aluminum adjuvant triggers a local inflammatory cascade that produces soreness, redness, and swelling at the injection site, along with possible low-grade fever, fatigue, and headache. These are signs that the immune system is responding appropriately to the vaccine, not signs of an allergic reaction.
How it works
When a true allergic reaction to the hepatitis A vaccine occurs, it follows the Type I (IgE-mediated) hypersensitivity pathway. The patient must have been previously sensitized to a specific vaccine component — most plausibly neomycin or latex — through prior exposure. Upon re-exposure via vaccination, the allergen cross-links specific IgE antibodies bound to mast cells and basophils, triggering degranulation with release of histamine, tryptase, and other inflammatory mediators. This produces the classic symptoms of anaphylaxis: urticaria, angioedema, bronchospasm, and, in severe cases, hypotension. The reaction typically begins within minutes to one hour of vaccine administration. The vast majority of post-vaccination symptoms — including injection-site pain, fever, and fatigue — are not mediated by IgE and do not represent an allergic mechanism.
The second category is vasovagal syncope and anxiety-related symptoms. Needle phobia, pain at the injection site, and the stress of a medical visit can trigger fainting, dizziness, nausea, and pallor — symptoms that patients and providers sometimes misinterpret as an allergic reaction. True vasovagal episodes are benign and self-limited.
The third, rarest category is genuine IgE-mediated hypersensitivity. When this occurs, the responsible allergen is not the inactivated hepatitis A virus itself but a residual vaccine component: trace amounts of neomycin (an aminoglycoside antibiotic used in the manufacturing process of Havrix but not Vaqta), latex from the vial stopper or syringe plunger in older packaging, or, theoretically, aluminum adjuvant — though aluminum adjuvant allergy is itself extremely rare and poorly characterized. Gelatin, a known allergen in some other vaccines, is not present in hepatitis A vaccine formulations.
Risk factors to watch for
Known neomycin allergy
Patients with a confirmed IgE-mediated allergy to neomycin, an aminoglycoside antibiotic, may react to trace residual neomycin in Havrix (hepatitis A vaccine). Vaqta does not contain neomycin.
Latex allergy
Patients with severe IgE-mediated latex allergy may react to latex from vial stoppers or syringe plungers, though most modern vaccine packaging is latex-free.
Prior anaphylaxis to any vaccine
A history of anaphylaxis to a previous vaccine dose increases the likelihood of a reaction to subsequent vaccines, though cross-reactivity between unrelated vaccines is uncommon.
Mast cell disorders
Patients with systemic mastocytosis or mast cell activation syndrome may experience non-IgE-mediated mast cell degranulation triggered by the stress or trauma of injection.
The Allergy Cascade
Exposure
Allergen contact
Detection
Immune recognition
IgE Response
Antibody production
Mast Cells
Histamine release
Symptoms
Allergic reaction
1.Exposure
Allergen contact
2.Detection
Immune recognition
3.IgE Response
Antibody production
4.Mast Cells
Histamine release
5.Symptoms
Allergic reaction
How Is Hepatitis A Vaccine Allergy Diagnosed?
Diagnosing a true hepatitis A vaccine allergy requires a systematic approach that begins with a detailed history of the reported reaction. A board-certified allergist will ask specific questions: What symptoms occurred? How soon after vaccination did they begin? How long did they last? Were any treatments administered? The answers to these questions often distinguish between a common local reaction, a vasovagal episode, and a possible IgE-mediated event. If the history suggests a possible IgE-mediated reaction — particularly if hives, angioedema, or respiratory symptoms occurred within one hour of vaccination — the allergist may perform skin prick testing to the vaccine itself and to individual vaccine components. Neomycin is the most clinically relevant component to test, as it is present in trace amounts in Havrix. Latex testing may be indicated if the patient has a history of latex sensitivity. If skin testing is negative, a graded-dose challenge — administering the vaccine in progressively larger doses under medical supervision — can confirm that the patient tolerates the vaccine and clear the 'allergy' label. At-home allergy testing services such as Curex offer panels covering environmental allergens, but vaccine component allergy testing requires specialized in-office procedures performed by an allergist. The role of at-home testing in this context is to rule out coincident environmental allergies that may be causing symptoms mistakenly attributed to vaccination.
Detailed reaction history
The most important diagnostic tool is a thorough history of the reported reaction: timing, symptoms, duration, and treatment. This alone often distinguishes allergic from non-allergic events.
Skin prick testing to vaccine components
An allergist can perform skin prick testing to the hepatitis A vaccine itself and to individual components such as neomycin. A positive test with appropriate controls suggests IgE-mediated sensitization.
Graded-dose challenge
If skin testing is negative, the vaccine is administered in progressively larger doses (e.g., 10%, then 90% of the full dose) under medical supervision with emergency medications available.
Test from home with Curex
Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.
Take the allergy quizManaging Hepatitis A Vaccine Reactions
See how different approaches stack up for managing your allergy symptoms long-term.
Management of hepatitis A vaccine reactions is stratified by the type and severity of the reported event. For the common local and systemic post-vaccination symptoms — injection-site soreness, low-grade fever, fatigue — treatment is supportive and straightforward. Cool compresses to the injection site, acetaminophen or ibuprofen for discomfort (as directed by your doctor), and rest are typically sufficient. These symptoms do not contraindicate future vaccination.
For patients with a suspected IgE-mediated reaction, the first step is allergist evaluation to confirm or rule out true allergy. If allergy is confirmed, the specific trigger (neomycin, latex, or other component) is identified. Future vaccination may be possible using an alternative formulation that does not contain the offending allergen — for example, Vaqta instead of Havrix for a patient with confirmed neomycin allergy, since Vaqta does not contain neomycin.
For the very rare patient who requires hepatitis A vaccination but has a confirmed allergy to a component present in all available formulations, a graded-dose challenge under allergist supervision can safely deliver the vaccine. This involves administering the total dose in incremental fractions while monitoring for reactions, with emergency medications immediately available. Premedication with antihistamines is not recommended as it may mask early signs of anaphylaxis without preventing the reaction.
Supportive care for common reactions
Cool compresses, rest, and over-the-counter analgesics for injection-site pain and low-grade fever. These symptoms are normal and self-limited.
Acetaminophen (Tylenol), ibuprofen (Advil, Motrin) as directed by your doctor
Symptomatic relief within 24–48 hours for most patients
Alternative vaccine formulation
For patients with confirmed neomycin allergy, Vaqta (Merck) can be used instead of Havrix, as Vaqta does not contain neomycin in its manufacturing process.
Vaqta (hepatitis A vaccine, inactivated, Merck)
Equivalent immunogenicity to Havrix; avoids the neomycin allergen
Graded-dose challenge
For patients with confirmed allergy who require vaccination and have no alternative formulation, the vaccine is administered in incremental doses under allergist supervision with emergency medications available.
Hepatitis A vaccine administered in fractionated doses per published protocols
High success rate; most patients tolerate the full dose without reaction
Epinephrine for anaphylaxis (emergency)
For the exceedingly rare patient who experiences anaphylaxis after vaccination, intramuscular epinephrine is the first-line life-saving treatment and must be administered immediately.
Epinephrine auto-injector (EpiPen, Auvi-Q) or manual intramuscular injection
Rapidly reverses anaphylaxis when administered promptly; delays in administration increase morbidity and mortality risk
| Feature | Traditional | Allergy Shots (SCIT) | Immunotherapy (SLIT)Recommended |
|---|---|---|---|
| Treats root cause | No | Yes | Yes |
| Long-lasting relief | No | Yes | Yes |
| At-home treatment | Yes | No | Yes |
| No office visits | Yes | No | Yes |
| Low side effects | Partial | Partial | Yes |
| Estimated cost | Partial | Partial | Yes |
Traditional
- NoTreats root cause
- NoLong-lasting relief
- YesAt-home treatment
- YesNo office visits
- PartialLow side effects
- PartialEstimated cost
Allergy Shots (SCIT)
- YesTreats root cause
- YesLong-lasting relief
- NoAt-home treatment
- NoNo office visits
- PartialLow side effects
- PartialEstimated cost
Immunotherapy (SLIT)
Recommended- YesTreats root cause
- YesLong-lasting relief
- YesAt-home treatment
- YesNo office visits
- YesLow side effects
- YesEstimated cost
Is There Immunotherapy for Hepatitis A Vaccine Allergy?
Instead of masking symptoms, immunotherapy retrains your immune system.
Allergen immunotherapy — whether subcutaneous (allergy shots) or sublingual (allergy drops) — is not a treatment for vaccine component allergy. Immunotherapy is designed to desensitize patients to environmental aeroallergens (pollens, dust mites, pet dander, molds) and, in some cases, insect venoms. It is not used for drug or vaccine allergies, which are managed through avoidance, alternative formulations, and, when necessary, temporary desensitization protocols. Temporary desensitization — sometimes called 'drug desensitization' — is a distinct procedure from allergen immunotherapy. In drug desensitization, a patient with a confirmed IgE-mediated allergy to a necessary medication receives escalating doses of that medication over hours in an intensive care or monitored setting, inducing a temporary state of tolerance that lasts only as long as the drug is continuously present in the body. This approach has been used for antibiotics, chemotherapeutic agents, and, rarely, vaccines. However, for the hepatitis A vaccine, the existence of neomycin-free formulations (Vaqta) and the availability of graded-dose challenge protocols make formal desensitization almost never necessary. If you also have IgE-mediated respiratory allergies — hay fever, dust mite asthma, pet dander — sublingual immunotherapy drops, offered by providers like Curex with plan-specific pricing (https://getcurex.com/learn/curex-pricing), can address those separately. In a real-world Curex study of 2,897 patients on at-home sublingual immunotherapy (Tharpe et al., Frontiers in Allergy, 2026), clinically meaningful symptom improvement rose to 45% of patients by two years, quality-of-life improvement reached 90.7%, and adherence stayed above 90%, with no anaphylaxis reported. These environmental allergies are far more common than vaccine allergy and are the appropriate target for disease-modifying immunotherapy.
Confirm the true allergy
Allergist evaluation with skin testing to vaccine components distinguishes true IgE-mediated allergy from common post-vaccination symptoms.
Identify the specific allergen
Determine whether neomycin, latex, or another component is responsible, which guides the choice of alternative formulation.
Select alternative or graded challenge
Use a neomycin-free vaccine (Vaqta) or perform a graded-dose challenge under allergist supervision to safely deliver the vaccine.
Document tolerance for future doses
After successful vaccination, document the outcome clearly in the medical record to prevent unnecessary vaccine avoidance in the future.
“Graded-dose challenge protocols have a very high success rate; most patients with reported vaccine allergy tolerate subsequent doses without reaction”
Rule out a true allergy, not just a vaccine side effect
If you're managing ongoing allergies beyond a one-time vaccine reaction, Curex's free quiz checks your eligibility for at-home testing and treatment.
- MD-ledBoard-certified allergists
- Plan-specificPricing · Confirm your quote
- 50K+Patients treated
- HSA/FSAEligible
Living With a Hepatitis A Vaccine Allergy Label
Carrying a 'hepatitis A vaccine allergy' label in your medical record has practical consequences that extend beyond the allergy itself. This label may trigger caution or refusal from healthcare providers when you need future vaccination, potentially leaving you unprotected against hepatitis A — a vaccine-preventable infection that can cause severe liver disease. The label may also create anxiety about other vaccines, even those with no shared components. The most important step for anyone with a reported hepatitis A vaccine allergy is to seek clarification from a board-certified allergist. In the majority of cases, the reported 'allergy' is actually a common post-vaccination symptom or a vasovagal episode, and the allergist can clear the label after appropriate evaluation. For the very small number of patients with a confirmed allergy, the allergist can identify the specific trigger and document which alternative formulation is safe, allowing future vaccination to proceed without restriction. Living with an unverified vaccine allergy label is unnecessary for most patients and carries more risk than the evaluation to resolve it.
Get your reaction evaluated
The majority of reported vaccine 'allergies' are not true allergies. A board-certified allergist can evaluate your history, perform testing if indicated, and often clear the label in a single visit.
Document safe alternatives
If a specific component allergy is confirmed, your allergist can document which alternative vaccine formulation is safe for you, ensuring future doses are not withheld unnecessarily.
Do not avoid all vaccines
A reaction to one vaccine does not mean you will react to others. Each vaccine has a unique component profile, and cross-reactivity between unrelated vaccines is uncommon.
Is There a Season for Hepatitis A Vaccine Reactions?
There is no seasonal pattern to hepatitis A vaccine reactions because the vaccine is administered year-round based on individual risk assessment and routine immunization schedules, not on environmental exposure cycles. The CDC recommends hepatitis A vaccination for all children at age 12–23 months, for travelers to endemic regions, for men who have sex with men, for people who use injection or non-injection drugs, for people experiencing homelessness, for people with chronic liver disease, and for others at increased risk. These indications are not seasonal, and vaccine administration occurs continuously throughout the year. Unlike pollen allergies, which follow predictable seasonal patterns driven by plant biology, vaccine reactions — when they occur — are driven by host factors (prior sensitization, mast cell disorders, anxiety) and vaccine-specific factors (components, lot variations) that are independent of calendar month. Any patient who reports a seasonal pattern to their post-vaccination symptoms should be evaluated for coincident environmental allergies rather than a true vaccine allergy.
January - December
low intensity
Preventing Hepatitis A Vaccine Reactions
Preventing hepatitis A vaccine reactions begins with accurate pre-vaccination screening. Patients should inform their healthcare provider of any known allergies — particularly to neomycin, latex, or any previous vaccine — before receiving the hepatitis A vaccine. This allows the provider to select the appropriate formulation (Vaqta for neomycin-allergic patients) and to prepare for any necessary precautions. For patients with a history of vasovagal syncope or needle phobia, receiving the vaccine while lying down or in a reclined position, with a 15-minute observation period afterward, can prevent fainting episodes and the subsequent misattribution of vasovagal symptoms as an allergic reaction. Staying well-hydrated and eating a light meal before vaccination also reduces vasovagal risk. For the very rare patient with a confirmed vaccine component allergy who requires hepatitis A vaccination, prevention means referral to a board-certified allergist for evaluation and, if indicated, a supervised graded-dose challenge rather than simply avoiding the vaccine. Avoiding a recommended vaccine carries its own risk — hepatitis A infection can cause severe liver injury, and the risk of infection in unvaccinated at-risk individuals far exceeds the minuscule risk of a true allergic reaction.
Disclose all known allergies
Tell your provider about any known allergies to medications, latex, or previous vaccines before vaccination so the appropriate formulation can be selected.
Lie down for vaccination if prone to fainting
Patients with a history of needle phobia or vasovagal syncope should receive the vaccine while lying down and remain reclined for 15 minutes afterward.
Stay for observation
The CDC recommends a 15-minute observation period after any vaccination to monitor for immediate reactions, even in patients with no allergy history.
Do not pre-medicate with antihistamines
Routine premedication with antihistamines before vaccination is not recommended, as it may mask early signs of anaphylaxis without preventing the reaction.
Consult an allergist for suspected reactions
If you believe you had an allergic reaction to a previous hepatitis A vaccine, see a board-certified allergist for evaluation before declining future doses.
Outlook for Hepatitis A Vaccine Allergy
The prognosis for patients with a reported hepatitis A vaccine reaction is excellent. The overwhelming majority of reported reactions are not true allergies and do not recur with subsequent doses. For the very rare patient with a confirmed IgE-mediated allergy to a vaccine component, the prognosis remains excellent because alternative formulations (neomycin-free Vaqta) and graded-dose challenge protocols allow safe vaccination in almost all cases. The key determinant of outcome is whether the patient seeks appropriate evaluation. Patients who avoid the vaccine without allergist consultation remain at risk for hepatitis A infection, which carries a far greater health risk than the minuscule risk of a true allergic reaction. Patients who undergo allergist evaluation typically have their 'allergy' label either cleared or managed with a specific plan, allowing them to receive the full recommended vaccine series and achieve long-term protection against hepatitis A.
Key takeaways
True IgE-mediated allergy to the hepatitis A vaccine is extraordinarily rare, occurring in approximately 1 per 1 million doses
The vast majority of reported 'reactions' are common, non-allergic post-vaccination symptoms that do not contraindicate future doses
For confirmed neomycin allergy, the neomycin-free Vaqta formulation provides a safe alternative to Havrix
Allergist evaluation with skin testing and graded-dose challenge can safely clear the 'allergy' label in almost all patients
Frequently Asked Questions
Yes, but true IgE-mediated allergy to the hepatitis A vaccine is extraordinarily rare, at roughly 1 per 1 million doses. When it occurs, the reaction typically targets a residual component such as trace neomycin or latex from older vial stoppers, not the inactivated virus itself. The overwhelming majority of symptoms after vaccination — soreness, redness, low-grade fever, fatigue — are normal immune responses, not allergic reactions. An allergist can distinguish a true allergy from a common post-vaccination symptom through history and, if indicated, skin testing.
Medical References
- [1]Centers for Disease Control and Prevention. Hepatitis A Vaccination: Information for Healthcare Providers. CDC, 2023.
- [2]Advisory Committee on Immunization Practices (ACIP). Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the ACIP. MMWR Recomm Rep, 2020.
- [3]McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol, 2018;141(2):463-472.
- [4]Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol, 2012;130(1):25-43.
- [5]Dreskin SC, Halsey NA, Kelso JM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J, 2016;9(1):32.
- [6]AAAAI. "The Importance of Vaccinations Across Age Groups."
- [7]Tharpe C, et al. Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform. Frontiers in Allergy. 2026;7:1865860.
- [8]Schaffer FM, Naples AR, Ebeling M, Hulsey TC, Garner LM. The safety of self-administered allergen immunotherapy during the buildup and maintenance phases. Int Forum Allergy Rhinol. 2015;5(2):149-156.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Ready to treat your Hepatitis A Vaccine allergies for good?
Get a personalized treatment plan from board-certified allergists, delivered to your door.
Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.
Compare Curex plan pricingQuestions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.